News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biogen Idec, Inc. (Massachusetts) (BIIB): European Medicines Agency’s Committee for Medicinal Products for Human Use Issues Positive Opinion on Marketing Authorization Application for FAMPYRA


5/20/2011 9:21:59 AM

Biogen Idec (NASDAQ: BIIB) announced today that FAMPYRA® (prolonged-release fampridine tablets) has been granted a positive opinion for conditional approval from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). Based on the CHMP recommendation, Biogen Idec expects that a marketing authorisation for FAMPYRA should be granted within 67 days.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES